secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2021-10-07T23:59:59+00:00
Accession:  0001193125-21-293760
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen doses first patient in Phase 1 trial of ACU193 for early Alzheimer's
---------------------------------------------------------------------------

- First patient dosed in INTERCEPT-AD Phase 1 trial of ACU193 for early Alzheimer's disease.
- ACU193 is the first monoclonal antibody selectively targeting toxic amyloid-beta oligomers (AβOs).
- Trial is placebo-controlled, single- and multiple-dose; enrollment ongoing.
- CEO Daniel O'Connell: ACU193 has distinct potential to address unmet needs in Alzheimer's.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312521293760/0001193125-21-293760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312521293760/d208321d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-293760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer